

The role of the Welsh Analytical Prescribing Support Unit (WAPSU)


AWMSG TRAINING DAY
Wednesday 16th January 2019


Kath Haines
Head of WAPSU
AWTTC



Overview

- Who are we?
- Role within AWTTC
- Current work streams
- Implementation
- Future developments and challenges
- How you can help us





WAPSU – Who are we?

- Work preliminarily started in 2010 as part of an ITS initiative
- Funding for establishment of WAPSU within WMP confirmed 2014
- Small team of pharmacists, technicians, scientists, writers, data analysts and administrators.
- Remit grown considerably over the years



WAPSU remit

- What was the expectation?
- Resources finite
- Assess the competition – need to duplicate??
- Added Welsh value is vital




Work programme

- Monitoring and analysis
- Medicines optimisation guidance and resources
- Financial forecasting
- Wales Patient Access Schemes administration



Monitoring and Analysis





Monitoring and Analysis

Illustrating trends in prescribing and other areas:

- NPIs
- New Treatment Fund
- Cost Efficiency initiatives:
 - Low priority for funding
 - Biosimilar implementation
- Patient Access Scheme uptake

NPI quarterly monitoring reports



National Prescribing Indicators 2018-2019

Analysis of Prescribing Data to June 2018




19. Analysis of Prescribing Data to June 2018

get or indicator threshold.

are, therefore the tick or cross demonstrates

Indicator	Hywel Dda UHB	Hywel Dda UHB	Powys Teaching UHB
11	2%	3%	2%
12	12%	15%	2%
13	1%	2%	1%
14	2%	3%	2%

Number of patients with a peptic ulcer who have been prescribed without a PPI as a percentage of all patients	15%	1%	3%	2%	2%	1%
Number of patients with a peptic ulcer who have been prescribed with a PPI as a percentage of all patients	✓	✓	✓	✓	✗	✓
% of antibiotic items per 1,000 STIB PDA	4%	4%	4%	4%	4%	4%
% of antibiotic items as a percentage of all antibiotic items	4%	4%	4%	4%	4%	4%
Proportion of antibiotic prescriptions suitable for single dose administration for surgical prophylaxis	✗	✗	✗	✓	✗	✗
Proportion of antibiotic prescriptions suitable for single dose administration for surgical prophylaxis	✗	✗	✗	✓	✗	✗



- Reports published quarterly.
- Data for quarter ending September 2018 due to be published shortly.
- Keep an eye on Twitter for the link.

Table 1. Prescribing Safety Indicators - Quarter

Number of patients with a peptic ulcer who have been prescribed without a PPI as a percentage of all patients

Number of patients with asthma who have been prescribed a beta 2 agonist as a percentage of all patients

Number of patients with concurrent prescriptions of verapamil and beta blocker as a percentage of all patients

Number of female patients with a past medical history of venous or arterial thromboses who have been prescribed combined hormonal contraceptives as a percentage of all female patients

Number of female patients with a current prescription of coxib/NSAID, as a percentage of all female patients

Number of patients with concurrent prescriptions of warfarin and an oral NSAID as a percentage of all patients

Number of patients under 12 with a current prescription of aspirin as a percentage of all patients

Number of patients aged 65 years or over prescribed an NSAID plus aspirin, as a percentage of all patients aged 65 years or over

Number of patients aged 65 years or over prescribed an antiplatelet, as a percentage of all patients aged 65 years or over

Number of patients aged 75 and over with an Anticholinergic Effect on Cognitive (AEC) score of 3 or more for items on active repeat, as a percentage of all patients aged 75 and over

Number of patients on the CCG register (1301) whose 3-ly after have received a repeat prescription for an NSAID within the last 3 months, as a percentage of all patients on the CCG register

Number of patients who are not on the CCG register but have an AEC 3 or 4 of 3 or more and have received a repeat prescription for an NSAID within the last 3 months, as a percentage of all patients who are not on the CCG register but have an AEC 3 or 4

3.0 ANALGESICS

There are three NPIs monitoring the usage of medicines used for the treatment of pain for 2018-2019:

1. Tramadol
2. Opioid analgesics
3. Gabapentin and pregabalin

3.1 Tramadol

Purpose: To encourage the appropriate use and review of tramadol in primary care, minimising the potential dependence, diversion, misuse and ADRs

Unit of measure: Tramadol DDOs per 1,000 patients

Aim: To reduce prescribing

Whilst there is a recognised place in pain management for tramadol, there are concerns regarding the risks associated with dependence, diversion, misuse and ADRs. This NPI promotes a prudent approach to prescribing tramadol, taking into account the risks and benefits, and encouraging timely review.



- Across Wales, prescribing of tramadol was 8.01% lower in the quarter ending June 2018, than in the equivalent quarter of the previous year. This is in line with the aim of the indicator.
- For the quarter ending June 2018, tramadol prescribing ranged from 415 to 652 DDOs per 1,000 patients across the health boards.
- The health board with the lowest prescribing was Powys Teaching UHB, whilst the highest prescribing was seen in Gwyn Taf UHB.
- Tramadol prescribing decreased compared with the equivalent quarter of the previous year in all of the health boards.
- The largest percentage decrease was seen in Hywel Dda UHB and the smallest percentage decrease was seen in Powys Teaching UHB.

National Prescribing Indicators 2018-2019, Analysis of Prescribing Data to June 2019

Table 3. Tramadol DDOs per 1,000 patients

Health Board	2017-2018 Qtr 1	2018-2019 Qtr 1	% Change
Hywel Dda	650	579	-11.0%
Gardf and Vale	573	522	-8.9%
Betsi Cadwaladr	589	557	-5.4%
Abertawe Bro Morgannwg	562	610	+8.7%
Aneurin Bevan	610	584	-4.3%
Gwyn Taf	701	652	-7.0%
Powys	427	413	-3.3%
Wales	625	573	-8.3%

Figure 2. Trend in tramadol prescribing DDOs per 1,000 patients





Server for Prescribing Information Reporting and Analysis


SPIRA dashboards:


- Low Priority for Funding Medicines
- National Prescribing Indicators
- Biosimilar Efficiencies




National Prescribing Indicators 2018-2019

- Prescribing Safety Indicators introduced in 2018-2019
- Suite of 12 indicators with a focus on safety
- Aim is to identify patients at high risk of ADRs and medicines related harm
- Data extracted from GP practices and aggregated to enable reporting at cluster and health board level
- GP practices able to access their own data and patient lists in order for review
- Role for practice and cluster pharmacists in reviewing these patients
- Cluster and health board data available on SPIRA





Cluster Desc	201803	201806	201809
Llanelli	1.60	1.65	1.74
Amman/Gwendraeth	1.32	1.40	1.44
Taf / Teifi / Tywi	1.35	1.38	1.35
North Ceredigion	1.28	1.30	1.29
South Ceredigion	1.05	1.11	1.17
North Pembrokeshire	1.03	1.10	1.11
South Pembrokeshire	1.02	1.12	1.07



Dashboard - 9 - Health Board Antibiotic Performance

Indicator Description
Antibacterial Items Per 1000 STAR-PU(13)


Antibiotic Target Data

A reduction of 5% against a baseline of data from April 2016 - March 2017

HealthBoard Desc	Antibacterial Items Per 1000 STAR-PU(13)							
	201606		201609		201612		201703	
	Values	% Reduction Target	Values	% Reduction Target	Values	% Reduction Target	Values	% Reduction Target
Abertawe Bro Morgannwg Uni	327.5	311.13	309.1	293.63	356.1	338.32	348.1	330.72
Aneurin Bevan	309.4	293.94	290.0	275.45	337.9	320.98	339.0	322.01
Betsi Cadwaladr Uni	309.8	294.32	299.1	284.11	344.3	327.12	335.1	318.35
Cardiff And Vale Uni	281.7	267.60	273.0	259.35	314.7	298.96	311.1	295.50
Cwm Taf	325.5	309.26	317.8	301.93	371.2	352.64	371.8	353.18
Hywel Dda	309.1	293.65	300.9	285.83	344.6	327.40	345.3	328.06
Powys Teaching	261.6	248.51	248.5	236.06	281.6	267.51	284.4	270.16

Latest Qtr Achievement

Antibacterial Items Per 1000 STAR-PU(13)



Latest Qtr Achievement vs Target Period

Antibacterial Items Per 1000 STAR-PU(13)

	Abertawe Bro Morgannwg Uni		Aneurin Bevan		Betsi Cadwaladr Uni		Cardiff And Vale Uni		Cwm Taf		Hywel Dda		Powys Teaching	
	201609	201809	201609	201809	201609	201809	201609	201809	201609	201809	201609	201809	201609	201809
Values	309.1	288.9	290.0	263.6	299.1	256.9	273.0	243.7	317.8	303.3	300.9	266.1	248.5	222.3
% Change		-6.55%		-9.09%		-14.09%		-10.75%		-4.56%		-11.54%		-10.52%

New Treatment Fund (NTF)

“The fund will support health boards to make all new medicines recommended by the National Institute of Health and Care Excellence and the All Wales Medicines Strategy Group available faster and more consistently across Wales.”

Vaughan Gething 10th January 2017





Welsh Health Circular – (2017) 001

“The directions require all health boards to make medicines recommended by NICE and AWMSG available as soon as is reasonably practicable and certainly within two months of the published recommendation.”


NTF dashboard — Smartsheet

Allows for remote data gathering and submission, with the benefit of real-time reporting of data via an easily accessible dashboard.

Case study



NTF dashboard developed in 2018:

- Allows health board representatives to remotely provide data on when newly appraised drugs have been made available on formulary
- This data is seamlessly collated to provide real time monitoring of compliance with the New Treatment Fund 60-day policy.



Total potential medicines to be added to formulary

162




Dashboard 2 - Basket Details by Health Board

Data to - September 2018

Drug Basket: Low Priority For Funding Paper 2
 Medicine Name: Omega-3 fatty acid compounds

Full Year projected outturn


Omega-3 fatty acid compounds Projected spend



Betsi Cadwaladr Uni

	2018-2019	2017-2018
Actual Spend	£113,111	£120,564
Difference in Actual		£7,454
% Difference in Act..		6.59%

Monthly Spend April Previous Financial Year to Date



Show YTD or projected FYE: YTD
 Show Spend or Items: Spend

YTD / Spend

Analysis by HB for Omega-3 fatty acid compounds

	SpendOrItems		Difference in SpendO..		% Difference in Spen..	
	17-18	18-19	17-18	18-19	17-18	18-19
Abertawe B.	37,221	35,821	-1,400		-3.76%	
Aneurin Be..	50,081	45,386	-4,695		-9.37%	
Betsi Cadw..	60,842	58,348	-2,494		-4.10%	
Cardiff And..	30,374	25,681	-4,692		-15.45%	
Cwm Taf	31,456	29,311	-2,144		-6.82%	
Hywel Dda	34,697	28,900	-5,797		-16.71%	
Powys Teac..	4,255	3,460	-794		-18.67%	
Grand Total	248,924	226,907	-22,016		-8.84%	

% Reduction generates Hypothetical Savings: 30.0

Hypothetical Savings YTD / Spend

SpendOrItems	Reduced To	Hypoth Savi..
37,221	26,054	-11,166
50,081	35,057	-15,024
60,842	42,589	-18,252
30,374	21,262	-9,112
31,456	22,019	-9,437
34,697	24,288	-10,409
4,255	2,978	-1,276
248,924	174,246	-74,677

What % changes in Spend have HBs seen for Omega-3 fatty acid compounds - YTD



Dashboard 1 - Biological Medicines Dashboard

The latest data available for analysis is **2018/2019 Qtr 2**

Biological medicine name

Etanercept ▾

Show YTD or projected FYE

YTD ▾

Full Year projected outturn

Current year data is represented by the *grey* histogram
Previous year data by the *red* line

Projected Outturn - *Spend* - Etanercept

Health Board	Spend		Absolute Change £		% Change %	
	2017/2018	2018/2019	2017/2018	2018/2019	2017/2018	2018/2019
ABMU	£1,486,250	£1,209,974	-£276,276	-18.59%		
Aneurin Bevan	£428,348	£506,388	£78,040	18.22%		
BCU	£956,196	£625,815	-£330,381	-34.55%		
Cardiff and Vale	£573,575	£483,332	-£90,243	-15.73%		
Cwm Taf	£414,042	£322,870	-£91,172	-22.02%		
Hywel Dda	£495,290	£484,234	-£11,056	-2.23%		
Grand Total	£4,353,700	£3,632,612	-£721,088	-16.56%		

Health Board

ABMU

£2,292,013

Aneurin Bevan

£840,880

BCU

£1,441,884

Cardiff and Vale

£1,030,510

Cwm Taf

£589,645

Hywel Dda

£992,962

NHS Wales

£7,187,914

YTD Items

Health Board	Items*		Absolute Change		% Change	
	2017/2018	2018/2019	2017/2018	2018/2019	2017/2018	2018/2019
ABMU	13,656	13,012	-644	-4.72%		
Aneurin Bevan	3,916	5,628	1,712	43.72%		
BCU	7,862	7,419	-443	-5.63%		
Cardiff and Vale	4,560	5,432	872	19.12%		
Cwm Taf	3,096	3,246	150	4.84%		
Hywel Dda	4,576	8,152	3,576	78.15%		
Grand Total	33,656	43,889	10,233	30.42%		

Projected Outturn - *Items* - Etanercept

Health Board

ABMU

24,916

Aneurin Bevan

8,420

BCU

17,019

Cardiff and Vale

11,552

Cwm Taf

6,246

Hywel Dda


16,648

NHS Wales


17,019

Patient Access Scheme Uptake

1. To develop a robust and efficient process for implementation of WPASs and PASs
2. To develop a clear communication network/system to facilitate the sharing of the necessary information
3. To review the use of all patient access schemes by individual health boards and trusts
4. To implement a central All Wales Patient Access Monitoring system




(W)PAS audit by scheme type in secondary care





■ Number of medicines reviewed
■ Medicines with potential missed savings

	Simple	Complex	CAA
Number of medicines reviewed	107	5	3
Medicines with potential missed savings	15	3	3




Audit findings – Primary care schemes






Audit findings - Complex schemes



- **Rebates/credits not claimed**
- **Difficulty reconciling rebates/credits received**
- **Electronic systems not user-friendly**
- **Administrative burden for busy clinicians and pharmacy teams**
- **Pharmacy teams reported poor responses to queries**
- **Pharmaceutical companies supportive & engaged with project team**



Medicines Optimisation Guidance and Resources









Technical and clinical edits by AWTTTC/WAPSU

Considered by AWPAG

Comments addressed and further edits

Wider consultation

Comments considered and addressed




Technical and clinical edits by AWTTTC/WAPSU

Considered by AWPAG

Comments addressed and further edits

Wider consultation

Comments considered and addressed




Comments
considered and
addressed

Sign-off from
AWPAG

Sign off from
AWMSG Steering
Committee

Presented to
AWMSG for sign-off

APPROVED




Comments
considered and
addressed

Sign-off from
AWPAG

Sign off from
AWMSG Steering
Committee


Presented to
AWMSG for sign-off

APPROVED




How you can help us...

Complete an NPPF if you would like to submit a project for consideration.




How you can help us...

Provide consultation responses while the document is being developed and forward consultations to colleagues.



Ongoing Medicines Optimisation Projects

- National Prescribing Indicators 2019–2020
- Therapeutic Priorities and CEPP Summary 2019–2020
- Conditions for which over the counter items should not routinely be prescribed in primary care
- All Wales COPD Management and Prescribing Guide
- Mental Health Medicines in Older Adults: the Adverse Drug Reaction (ADRe) Profile
- Multi-professional standard for medication review



Safe Use of Proton Pump Inhibitors

February 2018

All Wales Common Ailments Formulary

How you can help us...

Forward disseminated resources to colleagues.

Get in touch if you think a document needs update or review.

Have some feedback on our resources?
Please share it by completing our survey!

https://www.research.net/r/awmsg_resource_survey

February 2018
(Updated November 2018)

Primary Care Empirical Urinary Tract Infection Treatment Guidelines

February 2018


le:
y for
ion

Medicines Optimisation documents

Medicines Identified as Low Priority for Funding in NHS Wales – Paper 2

December 2018

Number of documents published in 2018 following process of editing, consultation and endorsement by AWPAG and AWMSG.



National Audit: Antipsychotics in Dementia

CEPP National Audit – Antipsychotics in Dementia

The aim of this audit is to ensure appropriate prescribing of antipsychotics in patients aged 65 years and over with a diagnosis of dementia. This will be achieved by measuring the degree to which prescribing of antipsychotics to patients aged 65 years and over is in line with current NICE guidance, and supporting the identification of patients where it may be appropriate to reduce or discontinue their antipsychotic prescription.

CEPP National – Antipsychotics in Dementia

First published: December 2018




All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

CEPP National Audit – Antipsychotics in Dementia


December 2018

Financial forecasting




Financial Forecasting

- Quarterly data to the Medicines Horizon Scanning and Forecasting Group
- Financial forecasting uses data from the appraisal process
- Projection based on historical spend
- Your input is crucial
 - Clinician appetite
 - Service implications




Wales Patient Access Schemes Administration




Wales Patient Access Schemes (WPAS)


- AWMMSG has accepted Wales Patient Access Schemes (WPAS) as part of its HTA process since 2010
- The process is based upon that of PASLU and 2014 PPRS
- Schemes may be simple or complex, and can include primary care dispensing of the medicine
- A total of 56 schemes have been submitted, 49 of which have been approved



Implementation



Share.awttc.org



AWTTTC
All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicolog Cymru Gyfan

SHARE – AWTTTC's Online Community

Welcome! Please use your **full name** and **NHS email address** to sign up. Follow forums and topics to keep up to date. Share and request examples of practice. Browse current topics or start a new one.

Forums | Subscribers | Staff | Online Users | Leaderboard

Forums


[Start new topic](#)

MEDICINES OPTIMISATION

- National Prescribing Indicators**
This is a forum for sharing your experiences of improving practice in line with the **AWMSB National Prescribing Indicators (NPIs)**. Please share stories and examples of initiatives, ask colleagues for advice and join in the discussion.
If you would like to discuss good practice in relation to a topic not included on this forum please start a discussion in Other Topics.
30 posts | Yellow Cards By Alexander Kiker (YCCS) 23 hours ago
- Other topics**
This is a forum for sharing your experiences of improving practice in other areas of prescribing and practice. Please share stories and examples of initiatives, ask colleagues for advice and join in the discussion.
If you would like to discuss good practice in relation to a topic not included please start a topic in this forum.
6 posts | DEPP National Audit: Antip... By Claire Thomas December 10, 2018
- Best Practice Day**
Slides and discussions coming out of the annual AWTTTC Best Practice Day.
37 posts | BPD 2018 - Medicines Monit... By admin September 16, 2018
- Networking groups**
This forum provides a space for groups to share and discuss organisational information. Please note. These forums are open and all SHARE users can see the discussion.
If you would like a forum added for your group, please email awttc@wales.nhs.uk and let us know.
3 posts | Pharmacy Prudent Innovatio... By Rhys Howell May 1, 2018

How you can help us...

Sign up to SHARE, comment on posted documents, post supporting work or implementation tools.



AWTTTC
All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicolog Cymru Gyfan

SHARE – AWTTTC's Online Community

Welcome! Please use your **full name** and **NHS email address** to sign up. Follow forums and topics to keep up to date. Share and request examples of practice. Browse current topics or start a new one.

Forums | Subscribers | Staff | Online Users | Leaderboard

Home > Medicines Optimisation > Best Practice Day > BPD 2018 - Facilitating Medicines Recycling

BPD 2018 - Facilitating Medicines Recycling

By admin, July 12, 2018 in Best Practice Day

Follow

Moderation Actions | Start new topic | Reply to this topic

admin (Advanced Member) | Administrators | 42 posts

Posted July 12, 2018 (edited) | Edited July 12, 2018 by admin

Julie Paton, Pharmacy Technician at Betsi Cadwaladr UHB, presented on 'Facilitating Medicines Recycling: A Waste of Time?' at the Best Practice Day 2018.

Slides from presentation by Julie Paton: Facilitating Medicines Recycling: A Waste of Time? [Facilitating Medicines Recycling - A Waste of Time post](#)

Watch the presentation from Julie Paton at the Best Practice Day 2018 here:


AWTTTC Best Practice Day 2018: Facilitating Medicines Recycling

All Wales Therapeutics and Toxicology Centre
Canolfan Therapiwteg a Thocsicolog Cymru Gyfan

Watch later | Share

2:55 / 12:40

- Set up as a forum for sharing good practice.
- Now includes dedicated forums for NPIs, Best Practice Day, networking groups, YCC, NTF.
- Links to health board initiatives, BPD slides and videos and discussions on all areas.
- Open to anyone with an NHS email address.
- Members can start discussions, post work, request help from others and follow discussions or members of interest.



Twitter

@AWTTCcomms

- Aim to increase reach with Twitter profile and keep followers up to date with latest news, events, published work, consultations

How you can help us...

Follow us on Twitter, set up notifications, and retweet.


AWTTC
@AWTTCcomms
All Wales Therapeutics and Toxicology Centre (AWTTC). Information, education and advice on medicines to improve patient experience and outcomes in Wales.
Wales, United Kingdom
awttc.org
Joined March 2017
40 Photos and videos

Medicines Identified as Low Priority for Funding in NHS Wales – Paper 2

Your Tweet Activity
Your Tweets earned **2,115 impressions** over the last **28 days**
[View your top Tweets](#)

Who to follow · Refresh · View all

- PIPCOP @pipcop [Follow](#)
- Reem El-Sharkawi @Ree... [Follow](#)
- Jonathan Simms @jon_si... [Follow](#)



AWTTC Newsletter

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwtg a Toxicoleg Cymru Gyfan

In Focus

WINTER 2018 ISSUE 05

Welcome to the AWTTC Newsletter!

Quarterly updates to keep you informed of our latest news and work.

Featuring news for October-December 2018 from:

- Welsh Analytical Prescribing Support Unit (WAPSU) 2
- Yellow Card Centre (YCC) Wales 3
- Welsh National Poisons Unit (WNPU) 3
- Patient Access to Medicines Service (PAMS) 4

This newsletter is published on the AWTTC website. Please e-mail awtttc@wales.nhs.uk if you would like us to add you to our mailing list or if you would like to give any feedback.

Best Practice Day presentations available to watch online
November 2018

Videos of each of the presentations from the Best Practice Day 2018 will be available from the day through a secure online platform to watch online. Videos, slides decks and additional information are also available to view on share.org

[Read more...](#)

AWTTC attends RPS Conference
November 2018

AWTTC was invited to attend the 6th Royal Pharmaceutical Society (RPS) YCC at Medicines Safety Conference on 22nd November 2018.

As well as having an exhibition stand to showcase the wide spectrum of activities undertaken by AWTTC, the Yellow Card Centre Wales team delivered one of the morning's workshops sessions entitled 'To be or not to be a safe' (see page 3).

[Read more...](#)

WAPSU
Welsh Analytical Prescribing Support Unit
Uned Cymorth Presgrioiwyr Ddeddfeddol Cymru

Analyzing prescribing data and developing medicines management strategies.

[Read more](#)

Guide to Prescribing Gluten-free Products
November 2018

This guide, updated in November aims to support GPs and other healthcare professionals in the management of patients with celiac disease and aid the decision making process for prescribing gluten-free foods.

[Read more](#)

Antipsychotics in dementia Audit
December 2018

A new national audit has been launched aiming to ensure prescribing of antipsychotic medicines is appropriate and overall a proportion of dementia is treated with a curative NICE guideline, supporting clinical outcomes that are where it may be appropriate to reduce or stop antipsychotic prescription.

[Read more](#)

Medicines Identified as Low Priority for Funding - Paper 2
December 2018

This document is part of ongoing work to minimise the cost of medicines with low clinical effectiveness or where more cost-effective treatments are available. Four medicines have been identified for this document:

- omeprazole
- gabapentin
- oxycodone and hydrocodone combination product
- paracetamol and tramadol combination product

[Read more](#)

Quarterly NPI report
December 2018

The First Nations Prescribing Indicator (NPI) report for Q3-2018 has been published, analysing data for the quarter ending June 2018. NPIs for Q3 2018 include indicators for many drug categories that have been categorised as 'red', 'amber' or 'green' efficiency indicators. The majority of these have a threshold endpoint prevalence across Wales, in line with the aim of each indicator compared to the equivalent quarter of the previous year.

[Read more...](#)

National Prescribing Indicators 2018-2019
<https://www.npsu.nhs.uk>

Coming soon - Biosimilar Best Practice Day 2019
Coming soon

The latest NPI report has a new category section in the shape of a similar disease areas & health boards in Wales, with the potential for significant cost savings. All health boards are invited to the workshop in the winter to discuss the best practice in biosimilars.

A Biosimilar Best Practice Day due to be held at Cardiff City Stadium on 21 January 2019 will provide a forum to share good practice initiatives, providing data, demonstrate change methodologies and procurement and commissioning information to support wider uptake of biosimilars in NI 18 Wales.

[Read more](#)

YCC Wales
Yellow Card Centre Wales
Canolfan Cerdyn Meyn Cymru

Analysing adverse reactions to medicines.

[Read more](#)

Supporter
2018

Welsh Medical Society (WMS) has been awarded the 2018 Member Healthcare Innovation award, to help make and support the time.

[Read more](#)

YCC at the RPS Medicines Safety Conference
November 2018

YCC Wales had a showcase session at the RPS conference entitled 'To be or not to be safe', presented by Dr Laurop Gwyn, Dr Iwan Jones and Dr Mark Drayton who explore how pharmacovigilance, safety culture and human factors influence patient safety.

[Read more](#)

ADR Awareness Week
November 2018

YCC Wales joined 27 medicines regulators from around the world in a Global Adverse Drug Reaction (ADR) Awareness Week. The theme of this year's campaign was 'Reporting side effects helps the safe use of medicines for babies, children and pregnant women'.

[Read more](#)

National Poisons Unit
Gwerwynnau Cenedlaethol Cymru

24-hour poisons advice to healthcare professionals.

[Read more](#)

2018 Update in Medical Toxicology Course
2018

Two day Update in Medical Toxicology Course in Cardiff on 19-20 October 2018 delivered by a group of five leading consultants in clinical toxicology covering topics:

- Panel leader overviews of chemical warfare agents, drugs and novel psychotropic substances
- Anticoagulants and their antidotes
- poisoning

Equipped with a wide range of practical real-life case studies and consultants in attendance to liaise with delegates over the two days. The next course is planned for Autumn 2019.

[Read more](#)

WeMeReC
Welsh Medicines Resource Centre
Canolfan Adhodddau Moduron Cymru

Providing education in the operation, prescribing and clinical management of medicines.

[Read more](#)

Access to Medicines Service
Canolfan Claf at Wesanaeth Hodydygiaethau

Working with technology providers and training the outputs of IT systems across Wales.

[Read more](#)

Pharmaceutical advice
December

The All Wales Pharmacy Group (AWMSG) has been awarded the 2018 'Pharmaceutical Advice' award for Wales.

[Read more](#)

AWMSG Masterclass for the pharmaceutical industry
November 2018

AWMSG has held its annual AWMSG Masterclass for the pharmaceutical industry at Cardiff City Stadium on 19 November 2018. The primary goal of these annual Masterclass days is to promote engagement from the pharmaceutical industry and answer any questions they may have regarding the approval process in Wales. It also provides an opportunity to network with people from AWMSG and AWTTC.

[Read more](#)

Pharmaceutical advice
December

The All Wales Pharmacy Group (AWMSG) has been awarded the 2018 'Pharmaceutical Advice' award for Wales.

[Read more](#)

AWMSG Masterclass for the pharmaceutical industry
November 2018

AWMSG has held its annual AWMSG Masterclass for the pharmaceutical industry at Cardiff City Stadium on 19 November 2018. The primary goal of these annual Masterclass days is to promote engagement from the pharmaceutical industry and answer any questions they may have regarding the approval process in Wales. It also provides an opportunity to network with people from AWMSG and AWTTC.

[Read more](#)

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwtg a Toxicoleg Cymru Gyfan


Contact us

Academic building, University Hospital, Llanoughor Road, Ewloe, Gwent, NP23 5TA

Telephone: 029 2071 6500
Email: awtttc@wales.nhs.uk
Web: www.awtttc.org

AWTTC NEWS WINTER 2018 - ISSUE 05

- Published quarterly with updates from WAPSU, PAMS, YCC Wales, WNPU and WeMeReC.
- Disseminated through CMO channels.
- Features all published work, news and events from that quarter.



Best Practice Days

Biosimilar Best Practice Day

21

January

Registrat

Save the date now, and register later in the year.


Best Practice Day 2019

9

July


Save the date!

Future Developments and Challenges



Future developments

- SPIRA development
- Medicines Safety dashboard
- Pathway apps increasing
- SAIL databank




Research project with SAIL Databank

- Currently working with the Secure Anonymised Information Linkage (SAIL) Databank on a pilot project, to link prescribing data to health outcomes.
- SAIL Databank includes information from GP systems, hospital admissions and other sources, stored in a way that provides information on individual patient experiences in an anonymised form.

Case study


Outcomes following discontinuation of dosulepin in patients in Wales:

- In order to reduce the risk of patients experiencing adverse effects associated with dosulepin, AWMSG introduced a National Prescribing Indicator (NPI) to monitor its usage in primary care in Wales in 2011.
- Using the SAIL Databank we will be able to investigate the outcomes of patients who discontinued dosulepin treatment and those who remained on treatment.
- Potential to correlate changes in prescribing that manifest as a result of the introduction of NPIs, to clinical outcomes experienced by patients.



Challenges

- Not all data is created equal and not all of it is easily accessible
- Cross the divide between clinical and financial realms
- Consider new resources or adding Welsh value to existing e.g. Open prescribing, PrescQIPP
- Success dependent on our sources
 - EPS data
 - 2D barcoding WP10s
 - Hospital prescribing data
 - Blueteq



Thank you



Diolch yn Fawr



How you can help us



Involvement in the process

- Complete an NPPF if you would like to submit a project for consideration
- Provide consultation responses while the document is being developed to support a robust process
- Forward consultations to colleagues to help us widen our reach among stakeholders

Engagement with published resources

- Check out our quarterly Newsletter which features news from across AWTTTC
- Follow us on Twitter (and set up notifications, retweet) to be informed of all newly published work
- Sign up to SHARE, comment on posted documents, post supporting work or implementation tools
- Forward disseminated resources to colleagues

Feedback on published work

- Complete feedback form to help us improve the usefulness of our resources
- Get in touch if you think a document needs update or review